Both studies further suggest that AML patients, who have a high mutational PI3K/AKT signaling activity potentially will benefit from combinatorial treatment with chemotherapy and DDR inhibitors and/or direct PI3K/AKT inhibitors or, alternatively, inhibitors of upstream PI3K/AKT activators such as KIT, FLT3, JAK2, ASXL1, and NRAS/KRAS. This evidence concerns the gene NRAS and acute myeloid leukemia.